CRNX Kapitalisasi Akuntansi Crinetics

Crinetics Pharmaceuticals (CRNX) develops highly specialized endocrine drugs, where high research risks are offset by colossal profits from monopoly patent sales. The market value dynamics of the asset, which reached 1.20, demonstrate the company's struggle against industry behemoths for leadership in the scientific race. Business prospects rely on the implementation of AI receptor modeling and the automation of laboratory peptide screening.

CRNX Kapitalisasi Buku Crinetics Corp (04.07.2022 - 12.09.2026)

Rincian metrik lan analitis perusahaan Crinetics (CRNX)

- rega lan prakiraan konsensus rega:

Kurs saham Crinetics Corp|CRNX - Target konsensus

- data kapitalisasi pasar:

Kapitalisasi pasar Crinetics Pharmaceuticals, Inc.|CRNX - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Buku Saham Crinetics|CRNX - Kapitalisasi Buku|Nilai Pasar marang Nilai Buku crinetics.com|CRNX - Total Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Crinetics Pharmaceuticals|CRNX - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Crinetics Pharmaceuticals, Inc.|CRNX - Utang perusahaan|Utang marang nilai buku Crinetics Pharmaceuticals, Inc.|CRNX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Crinetics

Pambiji fundamental:CRNX - Crinetics Corp

Barang unggulan Crinetics Pharmaceuticals, Inc.

For Crinetics Pharmaceuticals (CRNX), which automates drug synthesis using AI, the company's balance sheet capitalization reflects financial stability while conducting costly clinical trials. The current value of 1.20 measures the value of net assets, where excess liquidity may indicate inefficient capital management, while a deficit suggests risks of a deep drawdown in the issuer's fundamental basis.

Analisis pesaing Crinetics Pharmaceuticals